pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Opzelura
drug · small molecule
save

Opzelura

Marketedupdated 6mo ago
by $INCY INCYTE CORP🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 6 investigational indications.

targets

Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2

all catalysts(0)

nothing on the calendar yet

Trials studying Opzelura

  • phase2A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosisactive not recruitingn=33
  • phase3A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosisrecruitingn=105
  • phase1A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.completedn=476

Patent cliff

source: FDA Orange Book
first barrier falls
Nov 24, 2026
4 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (112)

  • May 5, 2041method-of-use (U-3550)US 11602536
  • Sep 4, 2040method-of-use (U-3505)US 11510923
  • Sep 4, 2040method-of-use (U-3505)US 11590137
  • Jul 28, 2040method-of-use (U-4151)US 12233067
  • Jun 10, 2040method-of-use (U-3551)US 11590138
  • Nov 20, 2031patentUS 10758543*PED
  • Nov 20, 2031patentUS 10869870*PED
  • Nov 20, 2031patentUS 11219624*PED
  • May 20, 2031formulationUS 107585434.5y
  • May 20, 2031method-of-use (U-3229)US 108698704.5y
  • May 20, 2031formulationUS 112196244.5y
  • May 20, 2031formulationUS 115714254.5y
  • May 20, 2031method-of-use (U-3404)US 115901364.5y
  • May 20, 2031formulationUS 122264194.5y
  • May 20, 2031formulationUS 125443814.5y
  • May 20, 2031formulationUS 125645934.5y
  • Dec 12, 2028patentUS 10016429*PED2.1y
  • Dec 12, 2028patentUS 10016429*PED2.1y
  • Dec 12, 2028patentUS 10016429*PED2.1y
  • Dec 12, 2028patentUS 10016429*PED2.1y
  • Dec 12, 2028patentUS 10016429*PED2.1y
  • Dec 12, 2028patentUS 10610530*PED2.1y
  • Dec 12, 2028patentUS 8722693*PED2.1y
  • Dec 12, 2028patentUS 8722693*PED2.1y
  • Dec 12, 2028patentUS 8722693*PED2.1y
  • Dec 12, 2028patentUS 8722693*PED2.1y
  • Dec 12, 2028patentUS 8722693*PED2.1y
  • Dec 12, 2028patentUS 8722693*PED2.1y
  • Dec 12, 2028patentUS 8822481*PED2.1y
  • Dec 12, 2028patentUS 8822481*PED2.1y
  • Dec 12, 2028patentUS 8822481*PED2.1y
  • Dec 12, 2028patentUS 8822481*PED2.1y
  • Dec 12, 2028patentUS 8822481*PED2.1y
  • Dec 12, 2028patentUS 8822481*PED2.1y
  • Dec 12, 2028patentUS 8829013*PED2.1y
  • Dec 12, 2028patentUS 8829013*PED2.1y
  • Dec 12, 2028patentUS 8829013*PED2.1y
  • Dec 12, 2028patentUS 8829013*PED2.1y
  • Dec 12, 2028patentUS 8829013*PED2.1y
  • Jun 24, 2028patentUS 7598257*PED1.6y
  • Jun 24, 2028patentUS 7598257*PED1.6y
  • Jun 24, 2028patentUS 7598257*PED1.6y
  • Jun 24, 2028patentUS 7598257*PED1.6y
  • Jun 24, 2028patentUS 7598257*PED1.6y
  • Jun 24, 2028patentUS 7598257*PED1.6y
  • Jun 24, 2028patentUS 8415362*PED1.6y
  • Jun 24, 2028patentUS 8415362*PED1.6y
  • Jun 24, 2028patentUS 8415362*PED1.6y
  • Jun 24, 2028patentUS 8415362*PED1.6y
  • Jun 24, 2028patentUS 8415362*PED1.6y
  • Jun 24, 2028patentUS 8415362*PED1.6y
  • Jun 12, 2028method-of-use (U-3230)US 100164291.6y
  • Jun 12, 2028method-of-use (U-3230)US 100164291.6y
  • Jun 12, 2028method-of-use (U-3230)US 100164291.6y
  • Jun 12, 2028method-of-use (U-3230)US 100164291.6y
  • Jun 12, 2028method-of-use (U-3230)US 100164291.6y
  • Jun 12, 2028method-of-use (U-3229)US 106105301.6y
  • Jun 12, 2028compositionUS 87226931.6y
  • Jun 12, 2028compositionUS 87226931.6y
  • Jun 12, 2028compositionUS 87226931.6y
  • Jun 12, 2028compositionUS 87226931.6y
  • Jun 12, 2028compositionUS 87226931.6y
  • Jun 12, 2028compositionUS 87226931.6y
  • Jun 12, 2028method-of-use (U-3229)US 88224811.6y
  • Jun 12, 2028method-of-use (U-3230)US 88224811.6y
  • Jun 12, 2028method-of-use (U-3230)US 88224811.6y
  • Jun 12, 2028method-of-use (U-3230)US 88224811.6y
  • Jun 12, 2028method-of-use (U-3230)US 88224811.6y
  • Jun 12, 2028method-of-use (U-3230)US 88224811.6y
  • Jun 12, 2028method-of-use (U-3228)US 88290131.6y
  • Jun 12, 2028method-of-use (U-3227)US 88290131.6y
  • Jun 12, 2028method-of-use (U-3227)US 88290131.6y
  • Jun 12, 2028method-of-use (U-3227)US 88290131.6y
  • Jun 12, 2028method-of-use (U-3228)US 88290131.6y
  • Dec 24, 2027compositionUS 75982571.1y
  • Dec 24, 2027compositionUS 75982571.1y
  • Dec 24, 2027compositionUS 75982571.1y
  • Dec 24, 2027compositionUS 75982571.1y
  • Dec 24, 2027compositionUS 75982571.1y
  • Dec 24, 2027compositionUS 75982571.1y
  • Dec 24, 2027compositionUS 84153621.1y
  • Dec 24, 2027compositionUS 84153621.1y
  • Dec 24, 2027compositionUS 84153621.1y
  • Dec 24, 2027compositionUS 84153621.1y
  • Dec 24, 2027compositionUS 84153621.1y
  • Dec 24, 2027compositionUS 84153621.1y
  • Jun 12, 2027patentUS 10639310*PED204d
  • Jun 12, 2027patentUS 9079912*PED204d
  • Jun 12, 2027patentUS 9079912*PED204d
  • Jun 12, 2027patentUS 9079912*PED204d
  • Jun 12, 2027patentUS 9079912*PED204d
  • Jun 12, 2027patentUS 9079912*PED204d
  • Jun 12, 2027patentUS 9079912*PED204d
  • Jun 12, 2027patentUS 9814722*PED204d
  • Jun 12, 2027patentUS 9814722*PED204d
  • Jun 12, 2027patentUS 9814722*PED204d
  • Jun 12, 2027patentUS 9814722*PED204d
  • Jun 12, 2027patentUS 9814722*PED204d
  • Jun 12, 2027patentUS 9974790*PED204d
  • Dec 12, 2026method-of-use (U-3229)US 1063931022d
  • Dec 12, 2026method-of-use (U-3230)US 907991222d
  • Dec 12, 2026method-of-use (U-3230)US 907991222d
  • Dec 12, 2026method-of-use (U-3230)US 907991222d
  • Dec 12, 2026method-of-use (U-3230)US 907991222d
  • Dec 12, 2026method-of-use (U-3230)US 907991222d
  • Dec 12, 2026method-of-use (U-3229)US 907991222d
  • Dec 12, 2026method-of-use (U-3230)US 981472222d
  • Dec 12, 2026method-of-use (U-3230)US 981472222d
  • Dec 12, 2026method-of-use (U-3230)US 981472222d
  • Dec 12, 2026method-of-use (U-3230)US 981472222d
  • Dec 12, 2026method-of-use (U-3230)US 981472222d
  • Dec 12, 2026method-of-use (U-3229)US 997479022d

FDA exclusivities (33)

  • Mar 22, 2029PEDPediatric (6mo bonus)2.3y
  • Mar 22, 2029PEDPediatric (6mo bonus)2.3y
  • Mar 22, 2029PEDPediatric (6mo bonus)2.3y
  • Mar 22, 2029PEDPediatric (6mo bonus)2.3y
  • Mar 22, 2029PEDPediatric (6mo bonus)2.3y
  • Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
  • Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
  • Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
  • Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
  • Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
  • Sep 18, 2028NPPNew Product (3y)1.8y
  • Nov 24, 2026PEDPediatric (6mo bonus)4d
  • Nov 24, 2026PEDPediatric (6mo bonus)4d
  • Nov 24, 2026PEDPediatric (6mo bonus)4d
  • Nov 24, 2026PEDPediatric (6mo bonus)4d
  • Nov 24, 2026PEDPediatric (6mo bonus)4d
  • Jun 19, 2026PEDPediatric (6mo bonus)
  • Jun 19, 2026PEDPediatric (6mo bonus)
  • Jun 19, 2026PEDPediatric (6mo bonus)
  • Jun 19, 2026PEDPediatric (6mo bonus)
  • Jun 19, 2026PEDPediatric (6mo bonus)
  • May 24, 2026ODE-238Orphan Drug (7y)
  • May 24, 2026ODE-238Orphan Drug (7y)
  • May 24, 2026ODE-238Orphan Drug (7y)
  • May 24, 2026ODE-238Orphan Drug (7y)
  • May 24, 2026ODE-238Orphan Drug (7y)
  • Jan 18, 2026PEDPediatric (6mo bonus)
  • Dec 19, 2025M-285Method (3y)
  • Dec 19, 2025M-285Method (3y)
  • Dec 19, 2025M-285Method (3y)
  • Dec 19, 2025M-285Method (3y)
  • Dec 19, 2025M-285Method (3y)
  • Jul 18, 2025I-896Indication (3y)

News(10)

  • Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
    Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
    biopharma_dive · 3d ago
  • Alethio raises $90M to target rare blood cancers
    The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.
    biopharma_dive · 14d ago
  • Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft
    Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…
    biospace · 16d ago
  • Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned merger
    In an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…
    fiercebiotech · 17d ago
  • Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid
    Geron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as N…
    fiercebiotech · 21d ago
  • ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
    Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.
    fiercebiotech · 25d ago
  • Merck KGaA bets on RNAi with $1.3B Silence buyout
    The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
    biopharma_dive · 1mo ago
  • Mid-cap biotechs join Trump’s latest round of drug pricing deals
    Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
    biopharma_dive · 2mo ago
  • 9 midsize drugmakers climb aboard Trump’s MFN train
    Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…
    biospace · 2mo ago
  • FDA OKs Takeda, Protagonist drug for rare blood cancer
    The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
    biopharma_dive · 2mo ago
view all news mentions →
brand
Opzelura
trade names
Jakafi, Jakavi, Opzelura
generic
ruxolitinib phosphate
MOA
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
indication
Hidradenitis Suppurativa
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 7h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?